Helix BioPharma Corp. Announces Fiscal 2009 Results
30th October 2009 AURORA, Ontario, October 30 /PRNewswire/ -- Helix BioPharma Corp. (TSX, FSE: HBP / OTCQX: HXBPF) today announced
financial results for the year ended July 31, 2009.
During the 2009 fiscal year,...
Torchmark Corporation Reports Third Quarter 2009 Results
28th October 2009 MCKINNEY, Texas, October 28 /PRNewswire/ -- Torchmark Corporation (NYSE: TMK) reported today that for the quarter
ended September 30, 2009, net income was US$1.22 per share compared with
US$.72 per...
Essilor - 2009 Third Quarter Report
22nd October 2009 CHARENTON-LE-PONT, France, October 22 /PRNewswire/ -- Essilor International, the world leader in ophthalmic optics,
today announced its consolidated revenue for the nine months ended September
30,...
STALLERGENES: Continued Dynamic Growth / Cumulative Sales to the end of September 2009 up 12%
15th October 2009 ANTONY, France, October 15 /PRNewswire/ --
Octapharma AG Announces Second Quarter 2009 Results and Mid Term Outlook of the Market
2nd October 2009 LACHEN, Switzerland, October 2 /PRNewswire/ -- Through June 2009, Octapharma AG realized a record turnover of 536 M
euro, compared to 422 M euro as of year-to-date June 2008, an increase of
27%.
...
Nucletron Increases Full Year Outlook After Strong First Half 2009
3rd September 2009 VEENENDAAL, the Netherlands, September 3 /PRNewswire/ -- Nucletron, a global leader in radiation oncology, today announced strong
financial results over the first half year of 2009. Despite...
Bavarian Nordic A/S - Half Year Interim Report 2009
28th August 2009 KVISTGAARD, Denmark, August 28 /PRNewswire/ -- Today Bavarian Nordic published the company's half-year interim report
2009. The full financial statements are available on the company's...
ThromboGenics NV Announces Business Update and Half Year Results 2009
27th August 2009 LEUVEN, Belgium, August 27 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology
company focused on the discovery and development of innovative treatments for
eye disease,...
Essilor : First Half 2009 Results
27th August 2009 PARIS, August 27 /PRNewswire/ --
STALLERGENES: 1st Half-Year 2009: Performance Ahead of Expectations
26th August 2009 PARIS, August 26 /PRNewswire/ -- The Board of Directors, meeting on 25 August 2009 under the
chairmanship of Albert Saporta approved the 2009 half year financial
statements:
Amsterdam Molecular Therapeutics Reports Half Year Results 2009
13th August 2009 AMSTERDAM, August 13 /PRNewswire/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in
the field of human gene therapy, today reported its results for the first
half year of 2009.
Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
5th August 2009 LONDON, August 5 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty
biopharmaceutical company, announces results for the three months to June 30,
2009.
Q2 2009 Financial...
Hoya Announces First Quarter Financial Results for FY2010
3rd August 2009 TOKYO, Japan, August 3 /PRNewswire/ -- HOYA Corporation today announced financial results for the first quarter
ended June 30, 2009. Net sales were 94.9 billion yen for the quarter, a 27.0%
decrease...
Misys - Preliminary Results Interview With CEO
23rd July 2009 LONDON, July 23 /PRNewswire/ -- Misys, the banking and healthcare software group, reported continued
growth despite the turmoil in financial markets.
The group's full year results have been...
GSK - Improving Performance to Continue in Second Half
22nd July 2009 LONDON, July 22 /PRNewswire/ -- GSK announced its sales and turnover fell by less than expected in Q2.
The Pharma giant also said there had been good growth in the consumer,
vaccine, european and...
Essilor : First Half 2009 Revenue
17th July 2009 CHARENTON-LE-PONT, France, July 17 /PRNewswire/ --
STALLERGENES: Strong Sales Growth in 1st Half-Year: up 12% Full-Year Guidance Maintained
15th July 2009 ANTONY, France, July 15 /PRNewswire/ --
© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd 
All rights reserved. Terms and Conditions | Contact us
